All In Biotech

Drug Trial Radar · NCT04178967

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis

A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.

Last checked: Nov 19, 2026Latest source record: May 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 445 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

445

Actual

Start

Oct 29, 2019

Primary completion

Jul 12, 2021

Study completion Apr 28, 2022

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
Dermira, Inc.
First posted
Nov 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.

Conditions

  • Atopic Dermatitis

Interventions

  • LebrikizumabBiological

    Subcutaneous injection

  • PlaceboOther

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16Time frame: Baseline to Week 16
  2. Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16Time frame: Baseline to Week 16

Locations

89 sites in 8 countries. Site status is shown where the registry gives one.

  • Investigate MD

    Scottsdale, Arizona

  • Northwest Arkansas Clinical Trials Center

    Rogers, Arkansas

  • Bakersfield Dermatology and Skin Cancer Medical Group

    Bakersfield, California

  • Center For Dermatology Clinical Research, Inc.

    Fremont, California

  • Woodward Centre

    Fresno, California

  • Dermatology Research Associates

    Los Angeles, California

  • LA Universal Research Center, INC

    Los Angeles, California

  • University Clinical Trials, Inc.

    San Diego, California

  • San Luis Dermatology & Laser Clinic

    San Luis Obispo, California

  • Clinical Physiology Associates, Clinical Study Center

    Fort Myers, Florida

  • Direct Helpers Medical Center

    Hialeah, Florida

  • The Community Research of South Florida

    Hialeah, Florida

  • Solutions Through Advanced Research, Inc.

    Jacksonville, Florida

  • Georgia Pollens Clinical Research Centers, Inc

    Albany, Georgia

  • Marietta Dermatology Clinical Research

    Marietta, Georgia

  • Advanced Medical Research

    Sandy Springs, Georgia

  • Arlington Dermatology

    Rolling Meadows, Illinois

  • NorthShore University HealthSystem

    Skokie, Illinois

  • Kansas City Dermatology, PA

    Overland Park, Kansas

  • Meridian Clinical Research

    Baton Rouge, Louisiana

  • ActivMed Practices and Research

    Beverly, Massachusetts

  • Tufts Medical Center

    Boston, Massachusetts

  • Great Lakes Research Group, Inc.

    Bay City, Michigan

  • Clarkston Skin Research

    Clarkston, Michigan

  • Associated Skin Care Specialists

    Fridley, Minnesota

  • Central Dermatology PC

    St Louis, Missouri

  • Forest Hills Dermatology Group

    Kew Gardens, New York

  • OnSite Clinical Solutions

    Charlotte, North Carolina

  • Wilmington Dermatology Center

    Wilmington, North Carolina

  • Dermatology and Skin Surgery Center

    Exton, Pennsylvania

  • DermDOX

    Hazleton, Pennsylvania

  • Peak Research LLC

    Upper Saint Clair, Pennsylvania

  • Dermatology & Laser Center of Charleston

    Charleston, South Carolina

  • Palmetto Clinical Trial Services

    Greenville, South Carolina

  • Arlington Research Center, Inc

    Arlington, Texas

  • Innovate Research, LLC

    Fort Worth, Texas

  • Austin Institute for Clinical Research

    Pflugerville, Texas

  • University of Utah MidValley Dematology

    Murray, Utah

  • Virginia Clinical Research, Inc.

    Norfolk, Virginia

  • Dermatology Associates

    Seattle, Washington

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.